When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors…
“The tech sector is once again outperforming the overall market in 2020 as investors continue to go all-in on growth,” observes the author of today’s article. However, the tech giants that have led the market’s rise may have limited upside left in the near term, and tech investors may be better off focusing on small-cap tech stocks. For seven high-quality…
Based on the premise that tech is poised to continue to drive the market for years to come, today’s article highlights three cheap (trading under $10 a share) stocks from the broader technology space to consider due to their growth prospects regardless of renewed market volatility. For more on these three tech stocks, CLICK HERE.
Shares of the small-cap biotech stock highlighted in today’s article have settled back down after surging more than 70% earlier this month in reaction to interim results for the company’s only drug candidate to reach the clinical trial phase. Does that make now a good time to buy? For more on this “flaming hot” biotech firm that could “become a…
While buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for…
The biotech stock highlighted in today’s article is one of the many that has surged over the last few months due to its status as a potential COVID-19 play, with the company in question being the producer of a COVID-19 test. As with all the smaller biotechs that have been experiencing COVID-19-related surges lately, however, the question is whether that…
In the current market environment, the author of today’s article notes that “As a stock picker, it’s important to find areas where the risk and reward proposition is more positive,” and advises that “One of the areas where this is best exhibited is with emerging markets.” He proceeds to highlight three emerging market stocks trading at big discounts based on…
The “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus…
Biotech stocks have been experiencing a healthy bounce, with the largest ETF that tracks the group recently hitting an all-time high following the announcement from Moderna that it was seeing early positive results with its coronavirus vaccine candidate. Some traders are cautioning investors to “tread carefully” when it comes to buying in to biotech stocks at their current levels, however,…
Anticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than…